CompaniesCellectar Biosciences
Cellectar Biosciences logo

Cellectar Biosciences

active
Florham Park, NJ, United States
Founded 2003
Website
About

Small Molecules

Areas of Focus

Categories

Small Molecule PharmaceuticalNJ, NY, PA
Team (8)
Asher Alban Chanan-Khan, MD.
Asher Alban Chanan-Khan, MD.
Director
Cellectar Biosciences
team_member
Chad Kolean
Chad Kolean
Chief Financial Officer
Cellectar Biosciences
executive
Douglas J. Swirsky
Douglas J. Swirsky
Chairman of the Board
Cellectar Biosciences
board_chair
Frederick W. Driscoll
Frederick W. Driscoll
Director
Cellectar Biosciences
team_member
James Caruso
James Caruso
President, CEO and Director
Cellectar Biosciences
executive
Jarrod Longcor
Jarrod Longcor
Chief Operating Officer
Cellectar Biosciences
executive
View all 8 team members →
Clinical Trials (15)
View all

Total Trials

15

As Lead Sponsor

11

As Collaborator

4

Total Enrollment

1,265

By Phase

PHASE1: 7PHASE2: 6PHASE3: 1

By Status

COMPLETED: 8ACTIVE_NOT_RECRUITING: 3WITHDRAWN: 2TERMINATED: 2
Clinical Trials Pipeline14 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
NCT00582283
NCT01662284
NCT02278315
NCT02952508
NCT03478462
NCT04105543
Hover over trial bars to see details

Recent Trials

NCT05610891Lead Sponsor
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
PHASE1Active, not recruiting
50 participants
Started: Oct 1, 2023 · Completed: Sep 30, 2026
NCT04105543Collaborator
CLR 131 Combined With Radiation for Head and Neck Cancer
PHASE1Completed
12 participants
Started: Dec 20, 2019 · Completed: Feb 1, 2024
NCT03478462Lead Sponsor
Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
PHASE1Active, not recruiting
30 participants
Started: Apr 30, 2019 · Completed: Dec 31, 2026
NCT02952508Lead Sponsor
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
PHASE2Active, not recruiting
120 participants
Started: Jul 26, 2017 · Completed: Dec 22, 2026
NCT02278315Lead Sponsor
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
PHASE1Completed
31 participants
Started: Feb 28, 2015 · Completed: Aug 10, 2022
View all 15 trials →
Funding History (20)
8-K
Oct 10, 2025
Filing
8-K
Oct 6, 2025
Filing
8-K
Aug 14, 2025
Filing
S-1/A
Jun 30, 2025
Filing
8-K
Jun 26, 2025
Filing
S-1
Jun 26, 2025
Filing
8-K
Jun 25, 2025
Filing
8-K
Jun 18, 2025
Filing
8-K
Jun 13, 2025
Filing
DEFA14A
Jun 11, 2025
Filing
Locations (1)
Headquarters
Florham Park, NJ, United States
Map

Loading map...